Skip to main content
MAXCYTE, INC. logo

MAXCYTE, INC. — Investor Relations & Filings

Ticker · MXCT ISIN · US57777K1060 LEI · 54930053YHXULRFCU991 US Professional, scientific and technical activities
Open in API
Filings indexed 767 across all filing types
Latest filing 2021-11-10 Interim / Quarterly Rep…
Country US United States of America
Listing US MXCT

About MAXCYTE, INC.

https://www.maxcyte.com/

MaxCyte, Inc. is a cell-engineering company that provides enabling platform technologies to advance the discovery, development, and commercialization of cell-based therapeutics. Its core offering is the ExPERT™ platform, which utilizes proprietary Flow Electroporation® technology for efficient, scalable, and non-viral transfection of complex cells. This technology supports a wide range of applications, including cell therapy, gene editing, antibody and protein production, and vaccine development. Additionally, MaxCyte offers SeQure™ genotoxicity assessment services to evaluate the safety of gene-edited products by detecting on- and off-target effects. The company employs a partnership-driven licensing model to support clients from early-stage research through to clinical and commercial manufacturing.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q3 2021
2021-11-10 English
FORM 8-K
Regulatory Filings
2021-11-10 English
Appointment of Chairman of the Board
Board/Management Information Classification · 1% confidence The document is an official announcement from MaxCyte, Inc. regarding the appointment of a new Independent Chairman of the Board, Richard Douglas, succeeding J. Stark Thompson. This falls directly under the category of changes in the company's board of directors or senior management. The document is distributed via RNS (Regulatory News Service), which is standard for such corporate announcements.
2021-11-03 English
FORM 8-K
Regulatory Filings
2021-11-02 English
Result of AGM
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled 'Result of AGM' and explicitly states that it is an announcement regarding the results of the Annual General Meeting held on October 29, 2021, including the status of resolutions passed. This falls directly under the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA).
2021-10-29 English
License with Nkarta, Inc.
Regulatory Filings Classification · 1% confidence The document is a press release distributed via the London Stock Exchange's RNS (Regulatory News Service) announcing a strategic platform license agreement between MaxCyte, Inc. and Nkarta, Inc. It details a business partnership and commercial agreement rather than a financial report, dividend, or governance update. Since it is a general regulatory announcement regarding corporate activity that does not fit into more specific categories like M&A or capital raising, it is classified as a Regulatory Filing (RNS).
2021-10-28 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.